|
Synonyms: RB-007 | RB007
Compound class:
Nucleic acid
Comment: Anivamersen (RB007) is a PEGylated antisense oligonucleotide (ASO) that binds via Watson-Crick base pairing to the coagulation factor IXa inhibiting RNA aptamer pegnivacogin (RB006). The pair were designed as complementary agents to induce and then rapidly reverse anticoagulation, primarily for application in the percutaneous coronary intervention (PCI) setting [2].
Full nucleotide sequence is: 2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidine |
| No information available. |
Summary of Clinical Use ![]() |
| Anivamersen (RB-007) was progressed as a clinical candidate antidote to the antidote to the anticoagulant effects of the factor IXa inhibitor pegnivacogin [1,3]. The phase 3 study NCT01848106 was terminated due to unacceptable serious drug-related adverse (allergic) reactions in subjects with preexisting anti-PEG antibodies. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01848106 | A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI | Phase 3 Interventional | Regado Biosciences, Inc. | The REGULATE-PCI trial | |